During the past decade, CH de Chateauroux conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 1 clinical trials were completed, i.e. on average, 25% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CH de Chateauroux" #1 sponsor was "University Hospital, Angers" with 3 trials, followed by "ARCAGY/ GINECO GROUP" with 1 trials sponsored, "Biotronik France" with 1 trials sponsored, "Centre Hospitalier Departemental Vendee" with 1 trials sponsored and "Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company" with 1 trials sponsored. Other sponsors include 2 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CH de Chateauroux" #1 collaborator was "AstraZeneca" with 1 trials as a collaborator, "Biotronik SE & Co. KG" with 1 trials as a collaborator, "Boehringer Ingelheim" with 1 trials as a collaborator, "Fund for Clinical Cardiovascular Research at LRD" with 1 trials as a collaborator and "Hoffmann-La Roche" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "CH de Chateauroux" are "Acute Coronary Syndrome" (2 trials), "Chronic Hepatitis C" (2 trials), "Quality of Health Care" (2 trials), "Atherosclerotic Cardiovascular Disease" (1 trials) and "Atrial Fibrillation" (1 trials). Many other conditions were trialed in "CH de Chateauroux" in a lesser frequency.

Most popular intervention types in "CH de Chateauroux" are "Drug" (5 trials), "Other" (3 trials), "Procedure" (2 trials), "Behavioral" (1 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Anti-EGFR agent (cetuximab +/- irinotecan or panitumumab)" (1 trials), "Bivalirudin" (1 trials), "Clopidogrel" (1 trials), "Computer-Assisted diagnostic Decision Support" (1 trials) and "Coronary angiography" (1 trials). Other intervention names were less common.

The vast majority of trials in "CH de Chateauroux" are 13 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "CH de Chateauroux". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in CH de Chateauroux, 1 suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in CH de Chateauroux, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 3 trials that are defined as “Not Applicable".